{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:35:39Z","timestamp":1768826139266,"version":"3.49.0"},"reference-count":28,"publisher":"The University of Occupational and Environmental Health, Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J UOEH"],"published-print":{"date-parts":[[2021,12,1]]},"DOI":"10.7888\/juoeh.43.379","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T22:11:17Z","timestamp":1639087877000},"page":"379-384","source":"Crossref","is-referenced-by-count":1,"title":["Eplerenone Improves Vascular Endothelial Function in Patients with Primary Aldosteronism: A Pilot Study","\u539f\u767a\u6027\u30a2\u30eb\u30c9\u30b9\u30c6\u30ed\u30f3\u75c7\u60a3\u8005\u306b\u304a\u3044\u3066\u30a8\u30d7\u30ec\u30ec\u30ce\u30f3\u306f\u8840\u7ba1\u5185\u76ae\u6a5f\u80fd\u3092\u6539\u5584\u3059\u308b\uff1a\u30d1\u30a4\u30ed\u30c3\u30c8\u7814\u7a76"],"prefix":"10.7888","volume":"43","author":[{"given":"Akira","family":"KUROZUMI","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.  Yahatanishi-ku, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"OKADA","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.  Yahatanishi-ku, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"TANAKA","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.  Yahatanishi-ku, Kitakyushu 807-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4637","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1.  Monticone S, Burrello J, Tizzani D <i>et al<\/i> (2017): Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice.  J Am Coll Cardiol 69 (14): 1811\u22121820","DOI":"10.1016\/j.jacc.2017.01.052"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2.  Baudrand R, Guarda FJ, Torrey J, Williams G & Vaidya A (2016): Dietary Sodium Restriction Increases the Risk of Misinterpreting Mild Cases of Primary Aldosteronism.  J Clin Endocrinol Metab 101 (11): 3989\u22123996","DOI":"10.1210\/jc.2016-1963"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3.  Piaditis G, Markou A, Papanastasiou L, Androulakis, II & Kaltsas G (2015): Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension.  Eur J Endocrinol 172 (5): R191\u2212203","DOI":"10.1530\/EJE-14-0537"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4.  Savard S, Amar L, Plouin PF & Steichen O (2013): Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study.  Hypertension 62 (2): 331\u2212336","DOI":"10.1161\/HYPERTENSIONAHA.113.01060"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5.  Tanabe A, Naruse M, Naruse K <i>et al<\/i> (1997): Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension.  Hypertens Res 20 (2): 85\u221290","DOI":"10.1291\/hypres.20.85"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6.  Umemura S, Arima H, Arima S <i>et al<\/i> (2019): The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).  Hypertens Res 42 (9): 1235\u22121481","DOI":"10.1038\/s41440-019-0284-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7.  Beswick RA, Dorrance AM, Leite R & Webb RC (2001): NADH\/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat.  Hypertension 38 (5): 1107\u22121111","DOI":"10.1161\/hy1101.093423"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8.  Ezekowitz JA & McAlister FA (2009): Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.  Eur Heart J 30 (4): 469\u2212477","DOI":"10.1093\/eurheartj\/ehn543"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9.  Hu LJ, Chen YQ, Deng SB, Du JL & She Q (2013): Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.  Br J Clin Pharmacol 75 (5): 1202\u22121212","DOI":"10.1111\/bcp.12012"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10.  Rubinshtein R, Kuvin JT, Soffler M <i>et al<\/i> (2010): Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events.  Eur Heart J 31 (9): 1142\u22121148","DOI":"10.1093\/eurheartj\/ehq010"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11.  Matsue Y, Yoshida K, Nagahori W <i>et al<\/i> (2014): Peripheral microvascular dysfunction predicts residual risk in coronary artery disease patients on statin therapy.  Atherosclerosis 232 (1): 186\u2212190","DOI":"10.1016\/j.atherosclerosis.2013.11.038"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12.  Torimoto K, Okada Y, Mori H & Tanaka Y (2013): Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus.  Cardiovasc Diabetol 12: 1","DOI":"10.1186\/1475-2840-12-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13.  Torimoto K, Okada Y, Mori H & Tanaka Y (2014): Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes.  Cardiovasc Diabetol 13: 99","DOI":"10.1186\/1475-2840-13-99"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14.  Torimoto K, Okada Y, Mori H <i>et al<\/i> (2015): Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.  Cardiovasc Diabetol 14: 25","DOI":"10.1186\/s12933-015-0188-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15.  Kurozumi A, Okada Y, Mori H <i>et al<\/i> (2016): Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes.  Endocr J 63 (5): 431\u2212440","DOI":"10.1507\/endocrj.EJ15-0623"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16.  Goshima Y, Okada Y, Torimoto K, Fujino Y & Tanaka Y (2020): Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus.  Sci Rep 10 (1): 15384","DOI":"10.1038\/s41598-020-72341-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17.  Tanaka K, Okada Y, Hajime M & Tanaka Y (2021): Low Vitamin D Levels are Associated with Vascular Endothelial Dysfunction in Patients with Poorly Controlled Type 2 Diabetes: A Retrospective Study.  J Atheroscler Thromb Jan 29.  doi: 10.5551\/jat.59113","DOI":"10.5551\/jat.59113"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18.  Bonetti PO, Pumper GM, Higano ST, Holmes DR, Jr., Kuvin JT & Lerman A (2004): Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia.  J Am Coll Cardiol 44 (11): 2137\u22122141","DOI":"10.1016\/j.jacc.2004.08.062"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19.  Funder JW, Carey RM, Mantero F <i>et al<\/i> (2016): The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.  J Clin Endocrinol Metab 101 (5): 1889\u22121916","DOI":"10.1210\/jc.2015-4061"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20.  Tsuchiya K, Yoshimoto T & Hirata Y (2009): Endothelial dysfunction is related to aldosterone excess and raised blood pressure.  Endocr J 56 (4): 553\u2212559","DOI":"10.1507\/endocrj.K09E-014"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21.  Nishizaka MK, Zaman MA, Green SA, Renfroe KY & Calhoun DA (2004): Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism.  Circulation 109 (23): 2857\u22122861","DOI":"10.1161\/01.CIR.0000129307.26791.8E"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22.  Chou CH, Chen YH, Hung CS <i>et al<\/i> (2015): Aldosterone Impairs Vascular Smooth Muscle Function: From Clinical to Bench Research.  J Clin Endocrinol Metab 100 (11): 4339\u22124347","DOI":"10.1210\/jc.2015-2752"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23.  Hao L, Kanno Y, Fukushima R, Watanabe Y, Ishida Y & Suzuki H (2004): Effects of eplerenone on heart and kidney in two-kidney, one-clip rats.  Am J Nephrol 24 (1): 54\u221260","DOI":"10.1159\/000075945"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24.  Kobayashi N, Hara K, Tojo A <i>et al<\/i> (2005): Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway.  Hypertension 45 (4): 538\u2212544","DOI":"10.1161\/01.HYP.0000157408.43807.5a"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25.  Sanz-Rosa D, Oubina MP, Cediel E <i>et al<\/i> (2005): Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences.  Antioxid Redox Signal 7 (9-10): 1294\u22121301","DOI":"10.1089\/ars.2005.7.1294"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26.  Nishizaka MK, Zaman MA, Green SA, Renfroe KY & Calhoun DA (2004): Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism.  Circulation 109 (23): 2857\u22122861","DOI":"10.1161\/01.CIR.0000129307.26791.8E"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27.  Macdonald JE, Kennedy N & Struthers AD (2004): Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.  Heart 90 (7): 765\u2212770","DOI":"10.1136\/hrt.2003.017368"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28.  Hundemer GL, Curhan GC, Yozamp N, Wang M & Vaidya A (2018): Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.  Lancet Diabetes Endocrinol 6 (1): 51\u221259","DOI":"10.1016\/S2213-8587(17)30367-4"}],"container-title":["Journal of UOEH"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/juoeh\/43\/4\/43_379\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T03:54:45Z","timestamp":1639194885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/juoeh\/43\/4\/43_379\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.7888\/juoeh.43.379","relation":{},"ISSN":["0387-821X","2187-2864"],"issn-type":[{"value":"0387-821X","type":"print"},{"value":"2187-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}